Evangelos Eleutherakis‐Papaiakovou

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos et al. · Blood Cancer Journal · 2021 · 128 citations · Full text

Veterinary Medicine, Immunology, Oncology +14

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

Evangelos Terpos, Efstathios Kastritis, D. Christoulas et al. · Annals of Oncology · 2012 · 111 citations · Full text

Medicine, Hematology, Oncology +16

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Meletios Α. Dimopoulos, Maria Gavriatopoulou, Erasmia Psimenou et al. · Blood Advances · 2017 · 105 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients

Lia A. Moulopoulos, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · American Journal of Hematology · 2012 · 96 citations · Full text

Medicine, Hematology, Oncology +17

Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

Meletios Α. Dimopoulos, Maria Gavriatopoulou, Erasmia Psimenou et al. · American Journal of Hematology · 2016 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11